GCTK Glucotrack (GCTK) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001506983
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter
Glucotrack insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Glucotrack, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 6.2% of the 2,951,257 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SYCOFF DREW bought about $230.0K of GCTK on Apr 22, 2024, the largest insider purchase at the company on our record; 11 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 83% of Medical Devices
Revenue
+378.3% year over year
more than 98% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
38.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 71% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GCTK
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-75.2%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GCTK: institutional holders (13F)
13F holdings, latest reported quarter
128,459 sh
$41.0K
79,530 sh
$25.4K
45,830 sh
$14.6K
34,207 sh
$10.9K
15,700 sh
$5.0K
Congress trades in GCTK
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GCTK planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
GCTK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$21.9K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$297 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Paul V. Goode
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$394.1K
$394.1K
$500.0K
n/a
n/a
2024
$350.0K
$349.6K
n/a
-95%
n/a
2023
$356.2K
$225.0K
$220.7K
-81%
n/a
2022
$485.7K
$200.6K
$175.0K
+41%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GCTK financials
Revenue growth
+378.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$70.8K
four quarters, 2019-10-01 to 2020-09-30
Revenue, TTM GCTK
| FY Dec 2025 | $70.8K |
| FY Dec 2024 | $70.8K |
| FY Dec 2023 | $70.8K |
| FY Dec 2022 | $70.8K |
| FY Dec 2021 | $70.8K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$16.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GCTK
| FY Dec 2025 | -$15.3M |
| FY Dec 2024 | -$12.6M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$4.0M |
| Sep 2025 | -$4.7M |
| Jun 2025 | -$3.7M |
| Mar 2025 | -$2.9M |
| Dec 2024 | -$3.5M |
| Sep 2024 | -$4.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-620.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -320.6% |
| FY Dec 2022 | -138.9% |
| FY Dec 2021 | -57.5% |
| Jun 2026 | -620.6% |
| Mar 2026 | -526.8% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -1,490% |
| Mar 2025 | -693.5% |
| Dec 2024 | n/a |
| Sep 2024 | -1,943% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-272.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GCTK
| FY Dec 2025 | -281.6% |
| FY Dec 2024 | -416.7% |
| FY Dec 2023 | -193.3% |
| FY Dec 2022 | -101.9% |
| FY Dec 2021 | -48.2% |
| Jun 2026 | -272.5% |
| Mar 2026 | -241.8% |
| Dec 2025 | -281.6% |
| Sep 2025 | -566.8% |
| Jun 2025 | -494.6% |
| Mar 2025 | -452.0% |
| Dec 2024 | -416.7% |
| Sep 2024 | -371.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-546.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GCTK
| FY Dec 2025 | -416.7% |
| FY Dec 2024 | -361.4% |
| FY Dec 2023 | -294.9% |
| FY Dec 2022 | -130.2% |
| FY Dec 2021 | -55.2% |
| Jun 2026 | -546.8% |
| Mar 2026 | -476.9% |
| Dec 2025 | -416.7% |
| Sep 2025 | n/a |
| Jun 2025 | -756.2% |
| Mar 2025 | -364.3% |
| Dec 2024 | -361.4% |
| Sep 2024 | -1,340% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.18x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing GCTK
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 44.58x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.04x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.14x |
| Sep 2024 | 1.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-95.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield GCTK
| FY Dec 2025 | -435.1% |
| FY Dec 2024 | -0.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -817.2% |
| Mar 2026 | -1,301% |
| Dec 2025 | -435.1% |
| Sep 2025 | -251.0% |
| Jun 2025 | -8.4% |
| Mar 2025 | -4.7% |
| Dec 2024 | -0.5% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -100%, PEG needs growth
PEG, trailing GCTK
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$16.1M | -$14.5M | -$7.1M | -$4.4M |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M |
| EPS (diluted) | 31.22 | 4,106.00 | 34.18 | 0.29 |
| Operating cash flow | -$15.2M | -$12.5M | -$6.6M | -$3.7M |
| Cash | $7.4M | $5.6M | $4.5M | $2.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
GCTK Stock Sonar score 4/7 axes
Find similar shapesCompareGCTK ranks highest on growth (98th percentile) and institutional and government (20th), and lowest on profitability (3rd), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
